A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Stephen Couban

doi:10.1016/j.clml.2021.06.011

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

Stephen Couban

Pharmacology, Toxicology and Pharmaceutics

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	766-774
Number of pages	9
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	21
Issue number	11
DOIs	https://doi.org/10.1016/j.clml.2021.06.011
Publication status	Published - Nov 2021

ASJC Scopus Subject Areas

Hematology
Oncology
Cancer Research

Keywords

Chronic lymphocytic leukemia, Ibrutinib, Bendamustine-rituximab, Phase III trial
Economic analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2021.06.011

Fingerprint

Dive into the research topics of 'A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia'. Together they form a unique fingerprint.

Cite this

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. / Couban, Stephen.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, No. 11, 11.2021, p. 766-774.

Research output: Contribution to journal › Article › peer-review

Couban, S 2021, 'A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia', Clinical Lymphoma, Myeloma and Leukemia, vol. 21, no. 11, pp. 766-774. https://doi.org/10.1016/j.clml.2021.06.011

@article{4850f6068a0a420a82eb1e20e35427dd,

title = "A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia",

keywords = "Chronic lymphocytic leukemia, Ibrutinib, Bendamustine-rituximab, Phase III trial, Economic analysis",

author = "Stephen Couban",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = nov,

doi = "10.1016/j.clml.2021.06.011",

language = "English",

volume = "21",

pages = "766--774",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "11",

}

TY - JOUR

T1 - A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

AU - Couban, Stephen

PY - 2021/11

Y1 - 2021/11

KW - Chronic lymphocytic leukemia, Ibrutinib, Bendamustine-rituximab, Phase III trial

KW - Economic analysis

UR - http://www.scopus.com/inward/record.url?scp=85111612266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111612266&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2021.06.011

DO - 10.1016/j.clml.2021.06.011

M3 - Article

C2 - 34334330

AN - SCOPUS:85111612266

SN - 2152-2650

VL - 21

SP - 766

EP - 774

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 11

ER -

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this